Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
testosterone · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | 2.5 mg testosterone gel |
| 2 | EXPERIMENTAL | 300 ug testosterone gel |
| 3 | PLACEBO_COMPARATOR | placebo gel |
| Name | Type | Description |
|---|---|---|
| testosterone gel | DRUG | 300 ug or 2.5 mg transdermal testosterone gel daily for 6 weeks |
| Comparator: placebo | DRUG | transdermal placebo gel for 6 weeks |
Inclusion Criteria: * Subject is at least 3 years postmenopausal * Subject is in good general health * Subject is willing to avoid excess alcohol or strenuous physical activity during the study Exclusion Criteria: * Subject has donated a unit of blood or has taken an investigational drug in anoth...
Low dose testosterone is an investigational small molecule being studied for skin androgenization and muscle anabolism. It is being developed by Merck & Company, Inc. (MRK) and is currently in Phase 1 clinical development. It has not been approved by the FDA and remains investigational.
Low dose testosterone is being developed by Merck & Company, Inc., which trades under the ticker MRK. The drug is currently in Phase 1 clinical trials for skin androgenization and muscle anabolism. It is an investigational small molecule and has not been approved for any use.
Low dose testosterone is in Phase 1 clinical development. It has completed two Phase 1 trials, one in muscle anabolism and one in skin androgenization. The drug is investigational and has not been approved by the FDA. Merck & Company, Inc. (MRK) is the developer.
Low dose testosterone has completed two Phase 1 trials. NCT00812396 studied biomarkers of muscle anabolism in 30 healthy male volunteers. NCT00969163 studied biomarkers of skin androgenization in 30 healthy female volunteers. Both trials were placebo-controlled and completed.
Low dose testosterone is a form of testosterone being studied at low doses for specific indications. It is being developed by Merck & Company, Inc. (MRK) for skin androgenization and muscle anabolism. The drug is in Phase 1 trials and is not FDA approved.